ProMIS Alzheimer’s Therapy Attacks Only Harmful Brain Protein, Unlike Other Treatments, Study Finds

ProMIS Alzheimer’s Therapy Attacks Only Harmful Brain Protein, Unlike Other Treatments, Study Finds
ProMIS Neurosciences’ Alzheimer’s therapy PMN310 attacks toxic forms of a protein linked to the disease but not normal forms, a preclinical-trial study indicates. Other therapies go after both forms of amyloid beta, giving PMN310 an important safety edge, ProMIS said. The study involved both human brain cells in a lab and mice. A key implication of the

Knowledge is power when living with alzheimers.

Get access to the web’s leading Alzheimer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

3 comments

  1. GEORGE ANDRE says:

    where does PMN310 stand in human clinical trials? What timeline are we looking at and is there any opportunity for AD patients to take part?
    caretaker for my wife with early stage AD

  2. Arthur B. says:

    Very promising. Hopeful.
    Their platform may make a significant difference in the lives of those affected by multiple neurological conditions.

Leave a Comment

Your email address will not be published. Required fields are marked *